معرفی
Ivo Gomperts Boneca is a permanent researcher and head of the Laboratory of Biology and Genetics of the Bacterial Cell Wall at the Institut Pasteur, Paris, within the Department of Microbiology. His research focuses on peptidoglycan (PGN) metabolism in bacterial pathogens such as Helicobacter pylori, Neisseria meningitidis, and Leptospira interrogans, examining both bacterial physiology and host immune responses. He leads major funded projects including ERC-2024-SyG-AI4AMR, which integrates artificial intelligence into antibiotic discovery, and participates in the INCEPTION convergence institute for interdisciplinary research.
- Institut Pasteur, Paris, France
- Department of Microbiology
- Laboratory of Biology and Genetics of the Bacterial Cell Wall
- Principal Investigator, ERC grants
- Member, INCEPTION program
His research interests center on understanding how the bacterial cell wall is assembled and remodeled during growth and division, and how PGN fragments influence host innate immunity. He investigates how pathogens modulate PGN to evade immune detection and how commensal bacteria contribute to gut homeostasis and disease prevention. His work bridges microbiology, immunology, and systems biology, with implications for antibiotic development and inflammatory disease treatment.
The recent publications reflect a strong trend in microbial cell wall biology, host-pathogen interactions, and the gut-immune-brain axis. Themes include PGN dynamics in host tissues, bacterial shape modulation, immune sensing mechanisms, and the role of microbiota in inflammation and cancer immunotherapy. The integration of AI in antimicrobial discovery highlights a forward-looking approach to combating antibiotic resistance.
- ERC-2007-Stg-202283-PGNfromSHAPEtoVIR
- ERC-2024-SyG-AI4AMR
- INCEPTION convergence program
Dr. Boneca mentors numerous PhD students and postdoctoral researchers, fostering a dynamic research environment. His lab receives substantial funding from the European Research Council and participates in collaborative, interdisciplinary grants. He leads projects on PGN assembly inhibition, gut microbiota effects on immunity and cancer therapy, and the development of optogenetic tools. His team includes research engineers, technicians, and administrative staff, reflecting a well-supported research structure.
He is affiliated with core research platforms at the Institut Pasteur, including those in bioimaging and microbiology. His laboratory is embedded within a network of interdisciplinary teams working on infectious diseases, immunity, and microbial evolution. The integration of computational and experimental approaches is evident in his participation in AI-driven drug discovery initiatives.
